Altimmune Inc.

11.78-0.4900-3.99%Vol 894.58K1Y Perf 257.16%
Apr 19th, 2021 16:00 DELAYED
BID11.71 ASK11.99
Open12.10 Previous Close12.27
Pre-Market- After-Market-
 - -  - -%
Target Price
42.67 
Analyst Rating
Strong Buy 1.00
Potential %
262.22 
Finscreener Ranking
★★★★★     62.11
Insiders Trans % 3/6/12 mo.
-100/-78/-78 
Value Ranking
★★★★+     59.49
Insiders Value % 3/6/12 mo.
-100/-91/-91 
Growth Ranking
★★★+     57.39
Insiders Shares Cnt. % 3/6/12 mo.
-100/-92/-92 
Income Ranking
 —    -
Market Cap437.63M 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
27.62 
Earnings Date
12th May 2021

Today's Price Range

11.5112.34

52W Range

2.8835.10

5 Year PE Ratio Range

-25.001.20

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-7.02%
1 Month
-28.26%
3 Months
-11.56%
6 Months
3.42%
1 Year
257.16%
3 Years
-44.69%
5 Years
-86.16%
10 Years
-90.02%

TickerPriceChg.Chg.%
ALT11.78-0.4900-3.99
AAPL134.840.68000.51
GOOG2 302.404.64000.20
MSFT258.74-2.0000-0.77
XOM56.48-0.1800-0.32
WFC43.880.04000.09
JNJ162.690.45000.28
FB302.24-3.9400-1.29
GE13.460.07000.52
JPM152.65-0.6500-0.42
Financial StrengthValueIndustryS&P 500US Markets
19.00
19.20
0.01
0.01
-5 779.90
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-665.30
-661.60
395.30
-
RevenueValueIndustryS&P 500US Markets
5.97M
0.16
-18.08
9.36
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.84-0.1779.76
Q03 2020-0.92-0.5441.30
Q02 2020-0.29-0.94-224.14
Q01 2020-0.32-0.2618.75
Q04 2019-0.26-0.253.85
Q03 2019-0.19-0.185.26
Q02 2019-0.25-0.26-4.00
Q03 2018-3.60-1.7351.94
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.39-208.33Negative
6/2021 QR-0.35-170.00Negative
12/2021 FY-0.59-203.51Negative
12/2022 FY2.892.48Positive
Next Report Date12th May 2021
Estimated EPS Next Report-0.39
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume894.58K
Shares Outstanding37.15M
Trades Count8.65K
Dollar Volume41.63M
Avg. Volume1.56M
Avg. Weekly Volume837.17K
Avg. Monthly Volume943.43K
Avg. Quarterly Volume1.61M

Altimmune Inc. (NASDAQ: ALT) stock closed at 11.78 per share at the end of the most recent trading day (a -3.99% change compared to the prior day closing price) with a volume of 895.98K shares and market capitalization of 437.63M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 43 people. Altimmune Inc. CEO is Vipin K. Garg.

The one-year performance of Altimmune Inc. stock is 257.16%, while year-to-date (YTD) performance is 4.43%. ALT stock has a five-year performance of -86.16%. Its 52-week range is between 2.88 and 35.1, which gives ALT stock a 52-week price range ratio of 27.62%

Altimmune Inc. currently has a PE ratio of -6.40, a price-to-book (PB) ratio of 2.02, a price-to-sale (PS) ratio of 76.32, a price to cashflow ratio of 0.10, a PEG ratio of 2.32, a ROA of -32.27%, a ROC of -33.95% and a ROE of -35.61%. The company’s profit margin is -%, its EBITDA margin is -661.60%, and its revenue ttm is $5.97 Million , which makes it $0.16 revenue per share.

Of the last four earnings reports from Altimmune Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.39 for the next earnings report. Altimmune Inc.’s next earnings report date is 12th May 2021.

The consensus rating of Wall Street analysts for Altimmune Inc. is Strong Buy (1), with a target price of $42.67, which is +262.22% compared to the current price. The earnings rating for Altimmune Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Altimmune Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Altimmune Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 24.90, ATR14 : 1.60, CCI20 : -161.11, Chaikin Money Flow : -0.21, MACD : -1.48, Money Flow Index : 46.46, ROC : -16.63, RSI : 39.19, STOCH (14,3) : 8.65, STOCH RSI : 0.00, UO : 39.97, Williams %R : -91.35), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Altimmune Inc. in the last 12-months were: David J. Drutz (Option Excercise at a value of $144), John M. Gill (Option Excercise at a value of $0), John M. Gill (Sold 8 425 shares of value $100 426 ), Klaus O. Schafer (Buy at a value of $23 980), Klaus O. Schafer (Option Excercise at a value of $0), Klaus O. Schafer (Sold 10 150 shares of value $100 587 ), Matthew Scott Harris (Sold 8 030 shares of value $80 461 ), Mitchel Sayare (Option Excercise at a value of $0), Philip L. Hodges (Option Excercise at a value of $0), Philip L. Hodges (Sold 9 727 shares of value $143 094 ), Wayne Pisano (Option Excercise at a value of $0), Wayne Pisano (Sold 10 352 shares of value $102 485 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Altimmune Inc.

Altimmune Inc is a United States-based clinical-stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of liver diseases. The firm's product candidates include NasoVAX, HepTcell, SparVax-L, and NasoShield. It also develops platform technologies such as RespirVec and Densigen. The company generates its revenue from cost plus fee contracts and fixed-price contracts.

CEO: Vipin K. Garg

Telephone: +1 240 654-1450

Address: 910 Clopper Road, Gaithersburg 20878, MD, US

Number of employees: 43

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

59%41%

News

Stocktwits